Loomis, Sayles & Company
CLVS

Loomis, Sayles & Company’s Clovis Oncology, Inc. CLVS Stock Holding History

Loomis, Sayles & Company’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-170,126
Closed -$10.3M – 801
2013
Q3 		$10.3M Sell
170,126
-357
-0.2% -$25.3K 0.03% 490
2013
Q2 		$11.4K Buy
+170,483
New +$7.67M 0.04% 449

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Loomis, Sayles & Company's CLVS Position: Q4 2013 in Review

Loomis, Sayles & Company sold out of Clovis Oncology, Inc. (CLVS) in Q4 2013, closing a stake of 170,126 shares — an estimated $10.3M sold.

Loomis, Sayles & Company first reported a position in CLVS in Q2 2013 and held it in 2 quarters. The position peaked at $10.3M in Q3 2013. 112 funds tracked by Wall St. Rank hold CLVS as of Q4 2013.

  • Loomis, Sayles & Company reported no remaining Clovis Oncology, Inc. position as of Q4 2013 after selling out during the quarter.
  • Loomis, Sayles & Company sold 170,126 Clovis Oncology, Inc. shares in Q4 2013, an estimated $10.3M.
  • Loomis, Sayles & Company first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 2 quarters.
  • Loomis, Sayles & Company's Clovis Oncology, Inc. position peaked at $10.3M in Q3 2013.
  • 112 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2013.

Based on Loomis, Sayles & Company's 13F filing for Q4 2013, filed 12 Feb 2014.